论文部分内容阅读
磷酸克林霉素是克林霉素的酯化衍生物,供静脉用药。本品为林可霉素类抗菌素,主要用于治疗革兰氏阳性菌及厌氧菌感染。本项研究用国产磷酸克林霉素与进口磷酸克林霉素随机对照及开放治疗急性细菌性感染52例,两药均每日静点2次,每次300mg,疗程7～14天。随机对照试验中,20例国产磷酸克林霉素与20例进口磷酸克林霉素总有效率分别为75.0％与80.0％,细菌清除率分别为85.7％与93.8％,不良反应发生率均为10.0％。本试验中用国产磷酸克林霉素共治疗呼吸道、皮肤软组织及外科感染32例,临床有效率81.3％,细菌清除率为92.3％,不良反应发生率为9.4％。
Clindamycin phosphate is an esterified derivative of clindamycin for intravenous use. This product is lincomycin antibiotics, mainly for the treatment of Gram-positive bacteria and anaerobic infections. In this study, 52 cases of acute bacterial infection were randomly controlled by open access and treated with domestic clindamycin phosphate and clindamycin phosphate. Both drugs were intravenously administered twice a day for 300 mg daily for 7 to 14 days. In the randomized controlled trials, the total effective rates of 20 cases of domestic clindamycin phosphate and 20 cases of imported clindamycin phosphate were 75.0% and 80.0% respectively, and the bacterial clearance rate was 85.7% and 93.8% respectively. The incidence of adverse reactions were 10.0%. In this experiment, 32 cases of respiratory tract, skin soft tissue and surgical infection were treated with domestic clindamycin phosphate. The clinical effective rate was 81.3%, the bacterial clearance rate was 92.3%, and the incidence of adverse reactions was 9.4%.